Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)

NCT00235482 is registered in ClinicalTrials.gov with Viralytics as lead sponsor.

NCT NCT00235482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00235482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)
Lead sponsor
Viralytics
Phase
Phase 1
Overall status
Completed
Start date
November 8, 2005
Completion date
April 21, 2006
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma